Growing prevalence of cancer is expected to be the major driver for the global antibody drug conjugate therapeutics market growth till 2026. According to the International Agency for Research on Cancer (IARC), in 2018, there were 18.1 million new cancer cases and deaths caused by cancer were estimated to be around 9.6 million. By 2030, these deaths are projected to reach 13 million, as per IARC estimates. The World Health Organization (WHO) predicts that new cancer cases will rise by 69% every year till 2030, causing a spike in the demand for antibody drug conjugate (ADC) therapeutics. The global antibody drug conjugate therapeutics market size will enlarge as a result.
Innovations and Collaborations to Spur Competition
Key players in the global antibody drug conjugate therapeutics market are increasingly focusing on developing novel products to strengthen their market position. For instance, Denmark-based biotech company, ADCendo, developed an ADC in August 2019 to treat metastatic soft tissue sarcoma. Additionally, companies are engaging in strategic collaborations to diversify their product portfolios. For example, UK-based AstraZeneca collaborated with Japan-based Daiichi Sankyo to develop an ADC that will deliver targeted treatment for cancer.
Fortune Business Insights profiles some of the major players in the global antibody drug conjugate therapeutics market:
- Bayer AG
- Pfizer Inc.
- Hoffman-Le Roche Ltd
- Seattle Genetics Inc.
- ImmunoGen Inc.
- Genentech, Inc.
- Synthon Holding B.V.
Fortune Business Insights, through its report, titled “Antibody Drug Conjugate Therapeutics Market Size, Share and Global Trend By Mechanism of Action (HER2 Antibodies, CD30 Antibodies, Anti-CD33 Antibody, CD22 Antibody), By Disease Indication (Blood cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026”, brings out a comprehensive analysis of the market. The report also contains a detailed evaluation of the factors, trends, and other dynamics that will influence the development of the market during the forecast period.
Antibody Drug Conjugates (ADCs) are highly potent monoclonal substances linked chemically to a drug. They bind themselves on specific receptors or proteins found on certain cells, which includes cancer cells. The drug enters the concerned cells and kills them, but does not harm other healthy cells. This makes them the ideal solution to kill cancer cells.
More Trending Topics From Fortune Business [email protected]